KKR will acquire Integer Holdings for $5.7 billion in cash, taking the medical-device contract manufacturer private and ending its listing that began in 1997. The purchase price values Integer at approximately $128 per share, a figure not yet disclosed but consistent with preliminary market settlement data. The transaction marks KKR's largest medtech CDMO acquisition and continues a pattern of PE firms withdrawing niche manufacturing platforms from public scrutiny.
Integer operates two core segments: cardiac rhythm management devices and neuromodulation components. The company supplies critical subassemblies to Medtronic, Boston Scientific, and Abbott, effectively embedding itself in the duopoly supply chain for pacemakers, ICDs, and spinal cord stimulators. Revenue for the twelve months ending June 2024 reached approximately $1.48 billion, with EBITDA margins near 22%—tight for a contract manufacturer but stable given the regulated nature of Class III device production. KKR inherits long-term supply agreements, FDA-registered cleanrooms across five countries, and a customer concentration risk that typically discourages public equity holders but appeals to sponsors capable of negotiating lock-in extensions.
The deal follows a broader shift in medtech M&A. Public valuations for single-product device makers compressed through 2023 as reimbursement uncertainty and GLP-1 spillover fears weighed on growth multiples. Integer, however, avoided direct exposure to those headwinds. Its business model—selling components, not finished goods—insulated it from payor negotiations and competitive undercutting. KKR is paying roughly 11.5x trailing EBITDA, a discount to the 13-15x range that prevailed for similar assets in 2021. The firm gains optionality: Integer can be run for cash, merged with another portfolio CDMO, or carved by segment if neuromodulation margins diverge from cardiac.
Allocators should watch three developments. First, whether KKR renegotiates Integer's Medtronic and Boston Scientific contracts before close—these typically contain change-of-control provisions that allow pricing resets. Second, FDA inspection timing: Integer's Tijuana and Reynosa facilities are due for routine audits in Q4 2024, and any observations could delay integration planning. Third, debt structure: KKR will likely lever the acquisition to 5.5-6.0x EBITDA, and the syndication of that debt—expected in September—will reveal sponsor appetite for medtech paper in a still-uncertain rate environment. If the term loan prices inside L+400, it signals confidence in the sector's resilience. If it widens past L+450, the market is pricing in execution risk or reimbursement concern.
The transaction is expected to close by year-end, subject to shareholder and regulatory approval. Integer's shareholders will receive cash and exit. KKR will own a manufacturing chokepoint in two of the three highest-margin device categories, with no obligation to report quarterly earnings or justify R&D cuts to activist funds.